(Q46746836)

24 December 2017

title

Prostate cancer in renal transplant recipients (English)

1 reference

24 December 2017

author name string

François Kleinclauss

1

1 reference

24 December 2017

Marc Gigante

2

1 reference

24 December 2017

Yann Neuzillet

3

1 reference

24 December 2017

Marc Mouzin

4

1 reference

24 December 2017

Nicolas Terrier

5

1 reference

24 December 2017

Laurent Salomon

6

1 reference

24 December 2017

François Iborra

7

1 reference

24 December 2017

Jacques Petit

8

1 reference

24 December 2017

Luc Cormier

9

1 reference

24 December 2017

Eric Lechevallier

10

1 reference

24 December 2017

Renal Transplantation Committee of the French Urological Association (AFU)

11

1 reference

24 December 2017

language of work or name

English

0 references

publication date

18 February 2008

1 reference

24 December 2017

Nephrology Dialysis Transplantation

published in

1 reference

24 December 2017

volume

23

1 reference

24 December 2017

issue

7

1 reference

24 December 2017

page(s)

2374-2380

1 reference

24 December 2017

Risk factors for cancer in renal transplant recipients

cites work

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN008

Excess risk of cancer in renal transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN008

Genitourinary malignancies in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN008

Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN008

Cyclosporine induces cancer progression by a cell-autonomous mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN008

Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN008

Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN008

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN008

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN008

Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN008

Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN008

Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN008

Patterns of malignancies following renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN008

Post-transplant de novo malignancies in renal transplant recipients: the past and present

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN008

Prostate cancer in the post-transplant population. Urologic Society for Transplantation and Vascular Surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN008

The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN008

Approach to management of clinically localized prostate cancer in patients with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN008

Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN008

Testosterone as a predictor of pathological stage in clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN008

Human herpesvirus 8 seroprevalence among prostate cancer case patients and control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN008

Plasma antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN008

The role of proliferation signal inhibitors in post-transplant malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN008

21 January 2018

Identifiers

DOI

10.1093/NDT/GFN008

1 reference

24 December 2017

1 reference

24 December 2017